The emergence of 2019 novel Coronavirus (COVID-19 or 2019-nCoV) has induced vital international morbidity and mortality with no consensus particular therapy. We examined the speculation that FDA-approved antiretrovirals, antibiotics, and antimalarials will successfully inhibit COVID-19 two main drug targets, coronavirus nucleocapsid...